Previous 10 | Next 10 |
Very favorable safety profile suitable for outpatient treatment, high complete response rate and strong durability observed, including patients with Waldenstrom macroglobulinemia and those who received prior CD19-directed CAR T therapy Expect to dose first patient in multicenter...
WORCESTER, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
Mustang Bio (NASDAQ:MBIO) said plans to begin a phase 1 trial combining CAR T cells and oncolytic virus to treat recurrent glioblastoma (rGBM), a type of brain cancer. The company said its decision was supported by interim data from two ongoing phase 1 trials evaluating two candidates, MB-108...
MB‐101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) are well tolerated in patients with recurrent GBM in ongoing Phase 1 clinical trials Data support potential of MB-109, the combination of MB-101 + MB-108, to optimize treatment ...
WORCESTER, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today ann...
Clinical-stage biotech, Mustang Bio (MBIO +25.8%), has recorded the sharpest intraday gain in more than two years Thursday despite reporting lower than expected financials for 4Q 2021. After the earnings, Cantor Fitzgerald noted that 2022 could be a “year of execution” for ...
Mustang Bio press release (NASDAQ:MBIO): FY GAAP EPS of -$0.76 misses by $0.03. As of December 31, 2021, Mustang’s cash and cash equivalents and restricted cash totaled $110.6 million, compared to $98.8 million as of December 31, 2020, an increase of $11.8 million year-to-date. Shares ...
WORCESTER, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
WORCHESTER, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, s...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...